Aurinia Pharmaceuticals (AUPH) Operating Income (2019 - 2026)

Aurinia Pharmaceuticals (AUPH) has 8 years of Operating Income data on file, last reported at $41.4 million in Q1 2026.

• Quarterly Operating Income rose 89.6% year-over-year to $41.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $124.5 million (up 309.33% YoY) and the FY2025 annual result came in at $104.9 million, up 2338.4% from the prior year.
• Operating Income climbed to $41.4 million in Q1 2026, from $33.2 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $41.4 million in Q1 2026 to a low of -$37.9 million in Q1 2022.
• A 5-year average of -$3.6 million and a median of -$9.5 million in 2022 frame the typical range for Operating Income.
• Annual changes were most pronounced in 2023 — Operating Income slumped 71.21% — and 2025, when it surged 2091.55%.
• Tracing AUPH's Operating Income over 5 years: stood at -$28.1 million in 2022, then fell by 5.6% to -$29.7 million in 2023, then surged by 94.38% to -$1.7 million in 2024, then surged by 2091.55% to $33.2 million in 2025, then grew by 24.62% to $41.4 million in 2026.
• The last three Operating Income figures came in at $41.4 million (Q1 2026), $33.2 million (Q4 2025), and $29.7 million (Q3 2025), per Business Quant data.